Whitehawk CEO to Discuss Oncology Innovation at TD Cowen Summit
Event summary
- Whitehawk Therapeutics CEO Dave Lennon, PhD, to participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026, at 11:00 AM ET.
- Event will provide insights for ASCO & EHA, with a webcast available for replay for 30 days.
- Whitehawk's three-asset ADC portfolio is in-licensed from WuXi Biologics under an exclusive global commercialization agreement.
The big picture
Whitehawk's participation in the TD Cowen Oncology Innovation Summit underscores the growing emphasis on next-generation ADC therapies in oncology. The company's focus on overcoming limitations of first-generation ADCs aligns with broader industry trends toward more targeted and effective cancer treatments. The strategic partnership with WuXi Biologics provides Whitehawk with a robust foundation for global commercialization, but execution will be key in a competitive oncology landscape.
What we're watching
- Pipeline Progress
- How Whitehawk's ADC portfolio advances through clinical stages will determine its competitive positioning in oncology.
- Commercial Strategy
- Whether the exclusive global commercialization agreement with WuXi Biologics can drive market penetration for Whitehawk's therapies.
- Investor Sentiment
- The pace at which Whitehawk can convert clinical progress into investor confidence and potential valuation uptick.
Related topics